Cardiovascular imaging technology developer Conavi Medical has raised about $20 million to commercialize its intravascular imaging system.
Novasight Hybrid enables simultaneous and coregistered imaging of coronary arteries with both intravascular ultrasound and optical coherence tomography. The system helps determine the size of an artery, as well as the nature and extent of any plaque.
The firm plans to raise an additional $10 million to support bringing this system to market. Novasight Hybrid already has 510(k) clearance from the U.S. Food and Drug Administration and regulatory approval for clinical use from Health Canada and the Ministry of Health, Labor and Welfare in Japan.
